PMID- 8022805
OWN - NLM
STAT- MEDLINE
DCOM- 19940801
LR  - 20210103
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 91
IP  - 14
DP  - 1994 Jul 5
TI  - Identification of a human melanoma antigen recognized by tumor-infiltrating 
      lymphocytes associated with in vivo tumor rejection.
PG  - 6458-62
AB  - The cultured T-cell line TIL1200, established from the tumor-infiltrating 
      lymphocytes (TILs) of a patient with advanced metastatic melanoma, recognized an 
      antigen on most HLA-A2+ melanomas and on all HLA-A2+ cultured neonatal 
      melanocytes in an HLA-A2 restricted manner but not on other types of tissues or 
      cell lines tested. A cDNA encoding an antigen recognized by TIL1200 was isolated 
      by screening an HLA-A2+ breast cancer cell line transfected with an expression 
      cDNA library prepared from an HLA-A2+ melanoma cell line. The nucleotide and 
      amino acid sequences of this cDNA were almost identical to the genes encoding 
      glycoprotein gp100 or Pmel17 previously registered in the GenBank. Expression of 
      this gene was restricted to melanoma and melanocyte cell lines and retina but was 
      not expressed on other fresh or cultured normal tissues or other types of tumor 
      tested. The cell line transfected with this cDNA also expressed antigen 
      recognized by the melanoma-specific antibody HMB45 that bound to gp100. A 
      synthetic 10-amino acid peptide derived from gp100 was recognized by TIL1200 in 
      the context of HLA-A2.1. Since the administration of TIL1200 plus interleukin 2 
      resulted in regression of metastatic cancer in the autologous patient, gp100 is a 
      possible tumor rejection antigen and may be useful for the development of 
      immunotherapies for patients with melanoma.
FAU - Kawakami, Y
AU  - Kawakami Y
AD  - Surgery Branch, National Cancer Institute, National Institutes of Health, 
      Bethesda, MD 20892.
FAU - Eliyahu, S
AU  - Eliyahu S
FAU - Delgado, C H
AU  - Delgado CH
FAU - Robbins, P F
AU  - Robbins PF
FAU - Sakaguchi, K
AU  - Sakaguchi K
FAU - Appella, E
AU  - Appella E
FAU - Yannelli, J R
AU  - Yannelli JR
FAU - Adema, G J
AU  - Adema GJ
FAU - Miki, T
AU  - Miki T
FAU - Rosenberg, S A
AU  - Rosenberg SA
LA  - eng
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA, Complementary)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Melanoma-Specific Antigens)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Adult
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antigens, Neoplasm/analysis
MH  - Cell Line
MH  - Cloning, Molecular
MH  - DNA, Complementary/metabolism
MH  - HLA-A2 Antigen/analysis
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Infant, Newborn
MH  - *Lymphocyte Transfusion
MH  - Lymphocytes, Tumor-Infiltrating/*immunology/pathology/*transplantation
MH  - Male
MH  - Melanocytes/immunology
MH  - Melanoma/*immunology/pathology/*therapy
MH  - Melanoma-Specific Antigens
MH  - Molecular Sequence Data
MH  - Neoplasm Proteins/*analysis/biosynthesis
MH  - Sensitivity and Specificity
MH  - Sequence Homology, Amino Acid
MH  - T-Lymphocytes/*immunology
MH  - Transfection
PMC - PMC44221
EDAT- 1994/07/05 00:00
MHDA- 1994/07/05 00:01
PMCR- 1995/01/05
CRDT- 1994/07/05 00:00
PHST- 1994/07/05 00:00 [pubmed]
PHST- 1994/07/05 00:01 [medline]
PHST- 1994/07/05 00:00 [entrez]
PHST- 1995/01/05 00:00 [pmc-release]
AID - 10.1073/pnas.91.14.6458 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458-62. doi: 
      10.1073/pnas.91.14.6458.